Quick Answer
Caris Life Sciences, Inc. reported Stockholders Equity of $577.31 million for fiscal year 2025.
Caris Life Sciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $577.31M | +123.1% |
| 2024 | -$2.50B | -16.5% |
| 2023 | -$2.14B | -26.0% |
| 2022 | -$1.70B | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $478.36M | +119.6% | +5.6% |
| June 30, 2025 | $452.90M | +119.2% | +117.4% |
| March 31, 2025 | -$2.60B | -14.3% | -4.0% |
| December 31, 2024 | -$2.50B | -16.5% | -2.3% |
| September 30, 2024 | -$2.44B | — | -3.5% |
| June 30, 2024 | -$2.36B | — | -3.7% |
| March 31, 2024 | -$2.27B | — | -6.0% |
| December 31, 2023 | -$2.14B | — | — |
- Caris Life Sciences, Inc. showed an increase of +123.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Caris Life Sciences, Inc.’s stockholders equity has grown by 133.9% (from -$1.70 billion to $577.31 million).
- The most recent figure is from Caris Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: